On the other hand, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, which are lipid clearance agents that inhibit PCSK9-mediated degradation of LDLR, have been linked to reductions in circulating LDL, reduced myocardial infarction risk and overall decreases in mortality in some populations (13, 168). Here, PCSK9 is linked to myocardial infarction.